tbuckley/cabot-search huggingface dataset:
Gemcitabine in combination with oxaliplatin as second-line therapy of advanced and metastatic NSCLC
Authors: A. J. Alencar, M. Blaya, L. Raez, N. Farfan, G. Lopes, G. Walker, A. Flores, J. Macintyre, C. Rocha-Lima
Journal: Journal of Clinical Oncology (2007)

18157 Background: Single agent gemcitabine is active as second line therapy in NSCLC. Oxaliplatin may be non-cross resistant with the other platinum-containing agents used as first-line therapy in NSCLC. The combination of gemcitabine and oxaliplatin (GEMOX) is synergistic in pre-clinical models. Methods: A phase II, non-randomized trial was designed to assess the efficacy and tolerability of gemcitabine 1,000 mg/m 2 over 100 min in combination with oxaliplatin 100 mg/m2 over 2 hours both given on days 1 and 15 of each 28-day cycle. Patients with NSCLC were eligible if they had progressed after first line treatment. Primary endpoint was tumor response rate. Planned sample size is 30 patients over a period of 2 years. Functional Assessment of Cancer Therapy- Lung (FACT-L) v.4 questionaire was used to assess quality of life of patients on therapy. Results: Twenty-two patients have been enrolled. 13 males (59%) and 9 females (41%). 15 Hispanic (68%), 4 Caucasian (18%), and 3 African-American (13%). Median age is 55 yrs. Histologic subtypes are as follows: adenocarcinoma, 12; NSCLC not otherwise specified 7; squamous cell carcinoma, 3. Nine patients had an ECOG performance status (PS) of 0 (41%) and 13 had a PS of 1 (59%). Two patients were never smokers. A total of 56 cycles have been administered (median 2, range 1 to 6). GEMOX as second-line therapy was given to 18 patients (81%), third-line to 4 patients (18%). Two patients died on study from disease progression leading to respiratory and multi-organ failure. The following Grade 3 and 4 adverse events were seen in 2 patients each: fatigue, dyspnea, anemia, and multi-organ failure. Cancer pain was seen in 1 patient. Twenty patients are available for assessment of response. Two patients had a confirmed partial response (10%) and another eight had stable disease (40%). Preliminary results of FACT-L analysis in 19 pts shows improvement in Lung Cancer Subscale (LCS) score in 25% of the patients after 2 cycles of therapy. Conclusions: Combination gemcitabine and oxaliplatin is active and well tolerated as second line treatment for NSCLC. Improvement of LCS score after 2 cycles suggests a clinical benefit that is beyond the observed response rate of 10%. No significant financial relationships to disclose.
Assessment of end induction minimal residual disease (MRD) in childhood B precursor acute lymphoblastic leukemia (ALL) to eliminate the need for day 14 marrow examination: A Children’s Oncology Group study.
Authors: Michael J. Borowitz, Brent L. Wood, Meenakshi Devidas, Mignon L. Loh, Elizabeth A. Raetz, Eric Larsen, Kelly W. Maloney, Andrew J Carroll, Alison M. Friedmann, Julie M Gastier-Foster, Nyla A. Heerema, Leonard A. Mattano, James B. Nachman, Naomi Joan Winick, William L. Carroll, Stephen Hunger
Journal: Journal of Clinical Oncology (2013)

10001 Background: Response to initial therapy is a powerful prognostic factor in pediatric ALL. Traditionally, slow early response (SER) has been defined by marrow morphology 8 or 15 days after start of induction therapy. More recently, MRD has been identified as the most important predictor of adverse outcome. The value of morphologic assessment of response in the setting of MRD has not been established. Methods: In COG studies AALL0331 (for NCI Standard Risk (SR) B ALL patients (pts)) and AALL0232 (High Risk (HR) B ALL pts), SER was defined by morphology as either ≥5% blasts in a day 15 marrow, or by flow cytometry as ≥0.1% MRD in a d29 marrow (SER MRD). Assignment to treatment arms also depended upon cytogenetic findings and extramedullary disease; each protocol had randomized treatment questions. SER pts were non-randomly assigned to receive augmented BFM therapy (ABFM) with 2 interim maintenance and delayed intensification phases (and CNS radiation for HR SER pts only). All pt treatment groups were combined for these analyses. Rapid early responders (RER) had a better outcome than SER pts (Table). However, pts who were SER only by morphology had a 5y DFS that was not significantly different from that of RER pts, and superior to that of pts who were SER MRD, or SER by both morphology and MRD. In multivariate analysis, SER by morphology was not an adverse prognostic factor after adjusting for risk group and MRD, or separately in SR or HR pts after adjusting for MRD. However, pts with .01-.1% MRD who were SER by morphology had a better 5y DFS than the.01-.1% MRD pts who were RER (90±6%, n=91 vs 77±3%, n=592). Only the former group received ABFM, suggesting intensification based on response rescues some poor risk pts. We conclude that a day 15 marrow is not needed to assess response if MRD is measured at end induction, provided that SER MRD is defined using a .01% cutoff, the threshold for intensifying therapy in current COG ALL trials. Clinical trial information: NCT00103285, NCT00075725. [Table: see text]
A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancy
Authors: Shweta R. Ugaonkar, Asa Wesenberg, Jolanta Wilk, Samantha Seidor, Olga Mizenina, Larisa Kizima, Aixa Rodriguez, Shimin Zhang, Keith Levendosky, Jessica Kenney, Meropi Aravantinou, Nina Derby, Brooke Grasperge, Agegnehu Gettie, James Blanchard, Narender Kumar, Kevin Roberts, Melissa Robbiani, José A. Fernández-Romero, Thomas M. Zydowsky
Journal: Journal of Controlled Release (2015)

Women urgently need a self-initiated, multipurpose prevention technology (MPT) that simultaneously reduces their risk of acquiring HIV-1, HSV-2, and HPV (latter two associated with increased risk of HIV-1 acquisition) and prevents unintended pregnancy. Here, we describe a novel core–matrix intravaginal ring (IVR), the MZCL IVR, which effectively delivered the MZC combination microbicide and a contraceptive. The MZCL IVR contains four active pharmaceutical ingredients (APIs): MIV-150 (targets HIV-1), zinc acetate (ZA; targets HIV-1 and HSV-2), carrageenan (CG; targets HPV and HSV-2), and levonorgestrel (LNG; targets unintended pregnancy). The elastomeric IVR body (matrix) was produced by hot melt extrusion of the non-water swellable elastomer, ethylene vinyl acetate (EVA-28), containing the hydrophobic small molecules, MIV-150 and LNG. The solid hydrophilic core, embedded within the IVR by compression, contained the small molecule ZA and the macromolecule CG. Hydrated ZA/CG from the core was released by diffusion via a pore on the IVR while the MIV-150/LNG diffused from the matrix continuously for 94 days (d) in vitro and up to 28d (study period) in macaques. The APIs released in vitro and in vivo were active against HIV-1ADA-M, HSV-2, and HPV16 PsV in cell-based assays. Serum LNG was at levels associated with local contraceptive effects. The results demonstrate proof-of-concept of a novel core–matrix IVR for sustained and simultaneous delivery of diverse molecules for the prevention of HIV, HSV-2 and HPV acquisition, as well as unintended pregnancy.
Oral Atorvastatin Treatment Improves NO Bioavailability and Vascular Redox State in the Human Arterial Wall, via a Tetrahydrobiopterin-Mediated Improvement of eNOS Coupling
Authors: Charalambos Antoniades, Costantinos Bakogiannis, Dimitris Tousoulis, Alexios S Antonopoulos, Regent Lee, Michael Demosthenous, Chandi Ratnatunga, Nikolaos Sfyras, Christodoulos Stefanadis, Keith M Channon
Journal: Circulation (2011)

Background: The exact mechanisms by which statins affect endothelial nitric oxide synthase (eNOS) biology in human atherosclerosis are unclear. We hypothesized that statin treatment improves nitric...
Medical Technology Assessment Directory: A Pilot Reference to Organizations, Assessments, and Information Resources
Authors: Goodman C
Journal: Annals of Internal Medicine (1988)

For the first time, a single reference identifies medical technology assessment programs. A valuable guide to the field, this directory contains more than 60 profiles of programs that conduct and report on medical technology assessments. Each profile includes a listing of report citations for that program, and all the reports are indexed under major subject headings. Also included is a cross-listing of technology assessment report citations arranged by type of technology headings, brief descriptions of approximately 70 information sources of potential interest to technology assessors, and addresses and descriptions of 70 organizations with memberships, activities, publications, and other functions relevant to the medical technology assessment community.
Sex differences in medical student mental health
Authors: C Lloyd, N K Gartrell
Journal: American Journal of Psychiatry (1981)

The authors studied first-year medical students to assess sex differences in psychological functioning. No initial sex differences in adjustment were found on any self-report measures. By mid-year, however, women students had developed more psychiatric symptoms and tended to report less satisfaction with life. By the year's end the women remained somewhat more symptomatic but to a lesser extent than had been apparent at mid-year. Women also reported more role conflict and described their families as less supportive of their career choice. The authors suggest that these findings point to the potentially negative impact of current medical training on women.
Radiaton pneumonitis with the combination of irinotecan and carboplatin concomitantly with radiation for stage III non-small cell lung cancer
Authors: L. E. Raez, G. Hatoum, B. R. Bastos, G. Walker, K. Tolba, N. Farfan, M. Karr, S. Kobina, V. Rodriguez, C. M. Rocha-Lima
Journal: Journal of Clinical Oncology (2008)

7582 Background: We evaluated the efficacy and safety of carboplatin (C) and irinotecan (I) concomitantly with radiation therapy followed by docetaxel (D) in patients (pts) with stages IIIA/B NSCLC. Methods: We enrolled 32 pts. The daily dose of radiation was 1.8 Gy, 5 days a week for 5 weeks, 25 fractions, (45 Gy) to the primary tumor and mediastinum (primary planning target volume: PPTV. After 45 Gy, the primary tumor and involved nodal metastasis (secondary planning target volume: SPTV) was boosted at 2 Gy per day to 18 Gy in 9 fractions. The total dose given was 63 Gy in 35 fractions over 7 weeks. C was given with an AUC=2 and I was given at 30mg/m2 both of them weekly for 7 weeks. D was given at 75mg/m2 as consolidation chemotherapy for 3 cycles. Results: Median age was 55 years (range: 42–78), most pts were females (74%), 57% were Caucasian and 57% were Hispanic. The most common histologies were poorly differentiated and squamous cell carcinomas. Half of the pts were stage IIIB. The overall response rate (ORR) was 63% (95%CI: 43.7 to 78.9%). Three pts achieved complete response (CR) and 17 pts partial response (PR). Also, 5 pts (16%) achieved stable disease (SD) for a disease control rate of 79% (63%+16%). Overall survival at 1 and 3 years were 55% (95% CI, 35% to 71%), and 34% (95% CI, 12% to 57%), respectively. Median survival was 16.6 months. Thirteen of 31 patients treated (41%) developed clinical radiation pneumonitis (RP). Clinical RP is expected in about 5–35% of pts treated with thoracic irradiation, and asymptomatic radiological findings might be found in as many as 50% of pts. The risk of RP depends on the dose and volume of lung exposed. Different literature data reported a correlation between the occurrence of RP of grade 2 or higher and dose-volumetric parameters (V20). If the V20 of pts treated is <31% then less than 10% of the pts will develop RP, however if the V20 >32% then 13–36% of the pts will develop RP. In our study the V20 was approximately 30%, for that reason we believe that the increase in the incidence of RP in our study is most probably due to this chemotherapy combination with radiation. Conclusions: The CI combination with radiation therapy is effective for the treatment of stage III NSCLC however the rate of RP might be too high for the expected toxicity. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration sanofi-aventis Pfizer, sanofi-aventis Pfizer, sanofi-aventis
Prediction of Tumor Treatment Response
Authors: J. Donald Chapman, Lester J. Peters, H. Rodney Withers
Journal: JNCI Journal of the National Cancer Institute (1986)

Journal Article Prediction of Tumor Treatment Response Get access JNCI: Journal of the National Cancer Institute, Volume 77, Issue 5, November 1986, Page 1173, https://doi.org/10.1093/jnci/77.5.1173 Published: 01 November 1986
Abstract 18575: Quantitative Assessment of Aortic Valve Calcification by Cardiac CT in the Penn Diabetes Heart Study: Association With Cardiovascular Risk Factors and Coronary Artery Calcium
Authors: Hashmi Rafeek, Tim Churchill, Suraj Rasania, Karen Terembula, Victor Ferrari, Claire Mulvey, Atif Qasim, Muredach Reilly
Journal: Circulation (2013)

Background: Aortic valve sclerosis is a common degenerative process defined by irregular calcification and thickening of the aortic valve leaflets without impairment in leaflet excursion. Aortic valve sclerosis (AVS) can progress to aortic valve stenosis. It has also shown to be associated with an increased frequency of myocardial infarction and mortality. Although thought to be increased among those with type 2DM, AVS has not been well characterized in this population. The aim of this study was to quantitatively measure AVS visualized on cardiac CT in a diabetic population and determine the risk factors associated with AVS. Methods: The Penn Diabetes Heart Study is a cross sectional study of T2DM subjects without coronary or renal disease. In all participants free of clinical aortic valve disease and with baseline electron beam cardiac CT, (N=1747, 63.5% male, 61% Caucasian) we quantified aortic valve calcium using the Agatston scoring method. Both logistic and tobit regression, with stepwise backward elimination, were used to examine association of AVS with CHD risk factors. Results: AVS was seen in 16.0% of participants. In multivariable logistic regression, AVS was independently associated with older age [OR 3.2, 95% CI (2.6-3.9), p&lt;0.001], male gender [OR 2.1 (1.5-3.0), p &lt;0.001], Caucasian race, and hypertension, [OR 2.45, (1.41-4.26), p&lt;0.001]. Associations were similar across increasing AVS Agatston scores in multivariable tobit regression. AVS was not associated with dyslipidemia, smoking, severity of diabetes, or CRP, but was associated with Lp(a) levels [OR 1.3 (1.12-1.50), p&lt;0.001]. The odds of AVS also increased across increasing levels of coronary artery calcium (CAC) [OR for CAC of 2.2 (1.3-3.8), p = 0.002 for AVS Agatston scores of &gt;0 to 100 and OR of 2.4 (1.1-5.3), p = 0.03 for AVS scores &gt;100) in fully adjusted logistic regression models. Conclusions: In diabetics, male gender, Caucasian race, older age, subclinical atherosclerosis and hypertension were independently associated with presence and extent of AVS, but many traditional CHD risk factors were not. This suggests that type 2 DM itself likely may contribute to the development of AVS. Whether AVS is part of the same process as CAC or forms via distinct mechanisms remains to be determined.
Cancer of the Lung and Other Intrathoracic Tumours.
Authors: Maurice Davidson
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pathogenic Micro-Organisms. A Text-Book of Microbiology for Physicians and Students of Medicine.
Authors: Ward J. MacNeal
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Preclinical Data In Cynomolgus (cyn) Monkeys Of ASTX727, a Novel Oral Hypomethylating Agent (HMA) Composed Of Low-Dose Oral Decitabine Combined With a Novel Cytidine Deaminase Inhibitor (CDAi) E7727
Authors: Aram Oganesian, Sanjeev Redkar, Pietro Taverna, Rajashree Joshi-Hangal, Mohammad Azab
Journal: Blood (2013)
Abstract 15598: The Ratio Between Bioprosthesis and CT-Measured Mean Annulus Diameter Predicts Significant Post-Procedural Aortic Regurgitation in Transcatheter Aortic Valve Implantation
Authors: Kentaro Hayashida, Erik Bouvier, Thierry Lefevre, Thomas Hovasse, Marie-Claude Morice, Bernard Chevalier, Mauro Romano, Philippe Garot, Arnaud Farge, Patrick Donzeau-Gouge, Bertrand Cormier
Journal: Circulation (2011)

Purpose: Post-procedural aortic regurgitation (AR) is known as an independent predictor for long-term mortality in transcatheter aortic valve implantation (TAVI), however the predictors for post-pr...
Abstract 17138: Pacemaker Utilization in Cohort of 85 Children with Congenital Central Hypoventilation Syndrome (CCHS) May Impact the Risk of Sudden Death
Authors: Sabrina Tsao, Gregory Webster, Pallavi P Patwari, Barbara J Deal, Debra E Weese-Mayer
Journal: Circulation (2011)

Background: Congenital Central Hypoventilation Syndrome (CCHS) is a rare disorder characterized by alveolar hypoventilation, autonomic dysregulation, and risk for prolonged sinus pause based on type of Paired-like Homeobox 2B ( PHOX2B ) mutation. Standard of care includes annual 72-hr Holter surveillance. Utility of implanted cardiac pacemakers (PM) and all-cause mortality have not been previously described. Hypothesis: Cardiac PM in CCHS will have minimal utilization and adverse effects, and may reduce mortality. Methods: CCHS diagnosis was confirmed with comprehensive clinical evaluation and (after 2003), PHOX2B testing. Indications for cardiac PM implantation, pacing burden and follow-up echo (to assess left ventricular dysfunction) were reviewed. Results: CCHS was confirmed in 85 pts (45% female). PM were implanted in 21 pts (mean age: 9 yr; range 0.8-22.6), all with PHOX2B 20/26 or 20/27 genotypes (known to heighten risk for cardiac pauses). Nineteen of the 21 PM pts (90.5%) had mild, atypical symptoms; 6/19 (32%) had overt symptoms including life-threatening events or seizures. Subsequent to the 2008 PHOX2B genotype/sinus pause risk publication (Pediatr Pulm 43:77-86), PM implantation was based on sinus pauses of ≥3 sec. In the pre-2008 cohort, all-cause mortality rate was 19.7% (12/61). In the 2008-present cohort, mortality rate was 2.9% (1/35)(p=0.03). Eleven pts overlapped cohorts; the 1 recently deceased PM pt had diffuse vasomotor instability, total gut aganglionosis, and continuous ventilator dependence. No device complications were observed in any pt. Mean burden of ventricular-pacing was 0.5% (range 0-2.4%). No ventricular dysfunction was noted in the 16/21 PM pts who had echo follow-up (mean follow-up 5.8 yrs, range 0.1-16.5). Conclusions: A strategy of annual 72-hr Holter monitoring and PM implantation for symptoms and/or asymptomatic pauses ≥ 3 sec is associated with reduced mortality in CCHS, though the reduction may be in part due to enhanced overall care during the study period. Devices had low utilization and complication rates and were not associated with ventricular dysfunction. We propose consideration of CCHS as a new category of pts who may require cardiac pacing to impact the risk of sudden death.
Richard Lower's Vindicatio: A Defence of the Experimental Method.
Authors: Ilza Veith
Journal: Annals of Internal Medicine (1984)

Lower's vindication of Thomas Willis's Diatriba de febribus (1659) against the attack of the Irish physician Edmund O'Meara (in Examen diatribae Thomae Willisii ... de febribus, London, 1665) is an important work in its own right.Lower was among
Our Mysterious Life Glands and How They Affect Us: A Popular Treatise on Our Glands and Their Secretions—What They Do to Us, How They Affect Our Health, Growth, Appearance, Temper, Mentality and Character, Including the Vitamins
Authors: William J. Robinson
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal